COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,363 Articles (22,803 medRxiv, 8,560 bioRxiv)

Most recent first Previous |  Page 962: Articles 9611-9620  | Next

Impact of SARS-CoV-2 variants on inpatient clinical outcome
Robinson, M. L., Morris, C. P., Betz, J., Zhang, Y., Thieman, D. R., Fall, A., Eldesouki, R. E., Norton, J. M., Gaston, D. C., Forman, M., Luo, C. H., Zeger, S. L., Gupta, A., Garibaldi, B. T., Mostafa, H. H.
10.1101/2022.02.02.22270337 — Posted: 2022-02-03
MACHINE LEARNING IMPACT ASSESSMENT OF CLIMATE FACTORS ON DAILY COVID-19 CASES
Afrifa, S., Ato Essien, F., Appiahene, P., Wiafe, I., Owusuaa Mensah Gyening, R.-M., Opoku, M.
10.1101/2022.02.03.22270399 — Posted: 2022-02-03
Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.
Osterdahl, M. F., Christakou, E., Hart, D., Harris, F., Shahrabi, Y., Pollock, E., Wadud, M., Spector, T. D., Brown, M. A., Seow, J., Malim, M. H., Steves, C. J., Doores, K. J., Duncan, E. L., Tree, T.
10.1101/2022.02.03.22270393 — Posted: 2022-02-03
At-Home Testing Study to Assess Risk Factors for Acquisition of SARS-CoV-2 Infection in a Major US Metropolitan Area
Woolley, A. E., Dryden-Peterson, S., Kim, A., Naz-McLean, S., Kelly, C., Laibinis, H. H., Bagnall, J., Livny, J., Ma, P., Orzechowski, M., Shoresh, N., Gabriel, S., Hung, D. T., Cosimi, L. A.
10.1101/2022.02.02.22269258 — Posted: 2022-02-03
SARS-CoV-2 Omicron variant, lineage BA.1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant.
Sentis, C., Billaud, G., Bal, A., Frobert, E., Bouscambert, M., Destras, G., Josset, L., Lina, B., Morfin, F., Gaymard, A., COVID-Diagnosis HCL Study Group
10.1101/2022.02.02.22269653 — Posted: 2022-02-03 Discussion: Onsite
Private Equity Acquisition in Ophthalmology and Optometry: A Time Series Analysis of the Pre-COVID, COVID Pre-Vaccine, and COVID Post-Vaccine Eras
Patil, S. A., Vail, D. G., Cox, J. T., Chen, E. M., Mruthyunjaya, P., Tsai, J. C., Parikh, R.
10.1101/2022.02.03.22270390 — Posted: 2022-02-03
Unraveling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent-RNA-Polymerase. An Unusual Active Site Leading to High Replication Rates.
Bignon, E., Monari, A.
10.1101/2022.02.02.478873 — Posted: 2022-02-03
Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
Chiu, W., Verschueren, L., Van den Eynde, C., Buyck, C., De Meyer, S., Jochmans, D., Bojkova, D., Ciesek, S., Cinatl, J., De Jonghe, S., Leyssen, P., Neyts, J., Van Loock, M., Van Damme, E.
10.1101/2022.02.02.478671 — Posted: 2022-02-03
COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism
Smeyne, R. J., Eells, J., Chatterjee, D., Byrne, M., Akula, S. M., Sriramula, S., O'Rourke, D., Schmidt, P.
10.1101/2022.02.02.478719 — Posted: 2022-02-03
Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)
Dhar, R., Kirkpatrick, J., Gilbert, L., Khanna, A., Modi, M. M., Chawla, R. K., Dalal, S., Maturu, V. N., Stern, M., Keppler, O. T., Djukanovic, R., Gadola, S. D.
10.1101/2022.01.30.22269685 — Posted: 2022-02-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).